Search Results - "Tretter, Christopher P.G."

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma by McDermott, David F, Regan, Meredith M, Clark, Joseph I, Flaherty, Lawrence E, Weiss, Geoffery R, Logan, Theodore F, Kirkwood, John M, Gordon, Michael S, Sosman, Jeffrey A, Ernstoff, Marc S, Tretter, Christopher P G, Urba, Walter J, Smith, John W, Margolin, Kim A, Mier, James W, Gollob, Jared A, Dutcher, Janice P, Atkins, Michael B

“…The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN)…”
Get full text

Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial by CLARK, Joseph I, ATKINS, Michael B, WEISS, Geoffrey R, REDMAN, Bruce G, TRETTER, Christopher P. G, MCDERMOTT, David, SMITH, John W, GORDON, Michael S, MARGOLIN, Kim A, URBA, Walter J, CREECH, Steven, FIGLIN, Robert A, DUTCHER, Janice P, FLAHERTY, Larry, SOSMAN, Jeffrey A, LOGAN, Theodore F, WHITE, Richard

“…This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell…”
Get full text

A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates by Choueiri, Toni K., Jacobus, Susanna J., Qu, Angela Q., Sweeney, Christopher, Appleman, Leonard Joseph, Tretter, Christopher P.G., Bubley, Glenn J., Elfiky, Aymen, Park, Rachel, Stack, Edward C., Signoretti, Sabina, Walsh, Meghara K., Steele, Graeme, Hirsch, Michelle S., Krajewski, Katherine Maragaret, Taplin, Mary-Ellen, Rosenberg, Jonathan E., Ross, Robert W.

“…Abstract only 278 Background: ddMVAC is associated with high responses rate (RR) in advanced urothelial cancer (UC). We embarked on a study in MIUC to…”
Get full text

Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF) by Schwaab, Thomas, Tretter, Christopher P.G., Gibson, Jennifer J., Cole, Bernard F., Schned, Alan R., Harris, Robert, Fisher, Jan L., Crosby, Nancy, Stempkowski, Laura M., Heaney, John A., Ernstoff, Marc S.

“…BACKGROUND Granulocyte monocyte‐colony stimulating factor (GM‐CSF) supports the survival, expansion, and differentiation of lymphoid and myeloid derived…”
Get full text

Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma by Schwaab, Thomas, Tretter, Christopher P, Gibson, Jennifer J, Cole, Bernard F, Schned, Alan R, Harris, Robert, Wallen, Eric M, Fisher, Jan L, Waugh, Mary G, Truman, Debra, Stempkowski, Laura M, Crosby, Nancy A, Heaney, John A, Ernstoff, Marc S

“…Biological therapy for renal cell carcinoma (RCC) uses agents that mobilize immune effector cells which are able to recognize and destroy cancer. We evaluated…”
Get more information

Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients by Crocenzi, Todd S., Tretter, Christopher P.G., Schwaab, Thomas, Schned, Alan R., Heaney, John A., Cole, Bernard F., Fisher, Jan L., Ernstoff, Marc S.

“…Classic T lymphocyte cytotoxicity is mediated through the T cell receptor (TCR). Defects in TCR signal transduction and cytolytic activity have been reported…”
Get full text